ArticleFrontiers in nutrition2025
Association between vitamin B6 status and liver fibrosis: evidence from NHANES 2005-2010.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liver fibrosis (LF) is a chronic liver disease with an increasing global prevalence, caused by various underlying factors. Vitamin B6 is significantly altered during inflammation and has been associated with diabetes and hypertension. To date, no study has explored the association between vitamin B6 and LF. We aimed to explore the association between vitamin B6 metabolites-4-pyridoxine acid (4-PA), pyridoxal 5'-phosphate (PLP), and the 4-PA/PLP ratio (an indicator of vitamin B6 metabolism rate in the body)-and LF risk. Methods: Data were extracted from the National Health and Nutrition Examination Surveys 2005-2010. Serum levels of 4-PA, PLP, and the 4-PA/PLP ratio were used to assess vitamin B6 status. The LF score was used to assess LF. Univariate and multivariate logistic regression tests were performed to explore the association between the vitamin B6 status and LF, using odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup analysis based on age, obesity, and several complications was also conducted. Results: Of the 8,063 subjects, 741 (9.19%) had LF. After adjusting all covariates, we observed that a high PLP level was associated with a lower risk of liver fibrosis (OR = 0.44, 95% CI: 0.35-0.56, Conclusion: In conclusion, a high serum PLP level was associated with lower odds of LF, whereas a high 4-PA/PLP ratio, representing an increased metabolic rate of vitamin B6, was associated with higher odds of LF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.